Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28845756 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL12478288 | 0.94 | MEN1 (0.51) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| Aniline SCHEMBL28196960 | 0.85 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL28055400 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL24775559 | 0.81 | CHRNB2 (0.52) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL9558480 | 0.80 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL6557404 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL1673367 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL1780308 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 | |
| SCHEMBL6179150 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4L3MBTL1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| CN-113412259-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-112089633-A | Oxidation dyeing method | 莱雅公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-105829315-B | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-106715419-A | Aminotriazine derivatives as TANK-binding kinase inhibitor compounds | 吉利德科学公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-105829315-A | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-104271576-A | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC | 2015-01-07 | — | — | CN | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20100144729-A1 | COUMARIN DERIVATIVES | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2109606-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | Novartis Ag (CH) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008092930-A1 | CHROMENE S1P1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| CN-1532193-A | Dimethyl-[1-(4-nitrophenyl) pyrrolidine-3-yl] amine | �ź㴫 | 2004-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144729-A1 | COUMARIN DERIVATIVES | F3, CYP3A7, CYP3A4 | CHRNB2 4228/4885CHRNA7 3419/4885CHRNA4 3962/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | CHRNB2 163/4885CHRNA7 132/4885CHRNA4 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.